📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis. (2022)

First Author: Schramm C

Attributed to: Stratified Medicine in Primary Biliary Cirrhosis (PBC): Understanding Disease Mechanisms and Targeting Therapies (UK-PBC) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jhepr.2022.100544

PubMed Identifier: 36267872

Publication URI: http://europepmc.org/abstract/MED/36267872

Type: Journal Article/Review

Volume: 4

Parent Publication: JHEP reports : innovation in hepatology

Issue: 11

ISSN: 2589-5559